Verily Life Sciences and Samsung Electronics America announced a collaboration that will bring together Samsung’s Galaxy Watch 8 with Verily’s precision health platform, Pre, to provide an integrated solution for generating evidence and monitoring real-world populations. Through this collaboration, Verily will fully integrate sensor data from the Samsung Galaxy Watch and make it accessible in its Viewpoint Evidence solution, which is built on the Verily Pre platform and enables research sponsors to run real-world studies with re-contactable participant cohorts. The partnership aims to accelerate research for life sciences and government customers by combining advanced health analytics with consumer-grade wearable data. Press release. 

Research Solutions announced the launch of Scite MCP, which enables researchers and developers to search scientific literature and evaluate the trustworthiness of research findings without leaving the AI tools they already use. While large language models can generate fluent text on most topics, their coverage of scholarly material is limited, and they struggle to distinguish well-supported findings from contested ones. Scite MCP solves this by giving AI tools direct access to over 250 million indexed articles, book chapters, preprints, and datasets, along with Scite's proprietary Smart Citations. The Scite MCP connects to ChatGPT, Claude, Microsoft Copilot, Cursor, Claude Code, and any AI tool that supports the Model Context Protocol standard. Key capabilities include answers grounded in trustworthy research, citation context, broad literature coverage, and works across tools. Press release. 

Johnson & Johnson announced that the U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. TECVAYLI and DARZALEX FASPRO work synergistically to prime and activate the immune system to eradicate myeloma cells that express the BCMA protein. This approval offers a potential new standard of care as early as second line and brings a novel treatment approach for the 40% of patients with multiple myeloma who experience disease relapse. Press release. 

Veristat expanded regulatory and clinical trial services to international pharmaceutical and medical device companies seeking a streamlined path into European, including the U.K. and Switzerland, plus Australian, Canadian, and U.S. markets. Particularly, Veristat has helped many Chinese companies — including Hansoh Pharma and CStone Pharmaceuticals — successfully navigate regional regulatory requirements and legal complexities leading to product approvals. Veristat is currently expanding to provide comprehensive regional clinical trial support. Press release. 

MODAG launched PD DETECT. With the world’s first CE-certified test kit for Parkinson’s disease, the company is making innovative Seed Amplification Assay technology broadly accessible as a standardized procedure for specialized diagnostic laboratories and hospitals for the first time. Developed in cooperation with the AESKU.GROUP, the kit contains all necessary components to precisely identify Parkinson’s patients at the molecular level with a sensitivity of 97.8% and a specificity of 100%. MODAG aims to decentralize diagnostics, make them broadly available, and establish biological certainty rather than clinical probability. Press release.